DK1636260T3 - Forbedret udskillelse af Neublastin - Google Patents

Forbedret udskillelse af Neublastin

Info

Publication number
DK1636260T3
DK1636260T3 DK04736510T DK04736510T DK1636260T3 DK 1636260 T3 DK1636260 T3 DK 1636260T3 DK 04736510 T DK04736510 T DK 04736510T DK 04736510 T DK04736510 T DK 04736510T DK 1636260 T3 DK1636260 T3 DK 1636260T3
Authority
DK
Denmark
Prior art keywords
neublastin
construct
region
nervous system
nucleotide sequence
Prior art date
Application number
DK04736510T
Other languages
English (en)
Inventor
Philip Kusk
Nels E Pederson
William P Sisk
Lars U Wahlberg
Mette Groenborg
Jens Tornoee
Original Assignee
Biogen Idec Inc
Nsgene As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Nsgene As filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DK1636260T3 publication Critical patent/DK1636260T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04736510T 2003-06-10 2004-06-10 Forbedret udskillelse af Neublastin DK1636260T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200300861 2003-06-10
US50748303P 2003-10-02 2003-10-02
PCT/DK2004/000411 WO2004108760A2 (en) 2003-06-10 2004-06-10 Improved secretion of neublastin

Publications (1)

Publication Number Publication Date
DK1636260T3 true DK1636260T3 (da) 2009-06-22

Family

ID=34485959

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09153016.2T DK2058329T3 (da) 2003-06-10 2004-06-10 Forbedret udskillelse af neublastin
DK04736510T DK1636260T3 (da) 2003-06-10 2004-06-10 Forbedret udskillelse af Neublastin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK09153016.2T DK2058329T3 (da) 2003-06-10 2004-06-10 Forbedret udskillelse af neublastin

Country Status (17)

Country Link
US (1) US7601518B2 (da)
EP (2) EP1636260B1 (da)
JP (1) JP5623685B2 (da)
KR (1) KR20060031618A (da)
CN (1) CN100475846C (da)
AT (2) ATE478092T1 (da)
AU (1) AU2004245175C1 (da)
BR (1) BRPI0411243A (da)
CA (1) CA2527914C (da)
DE (2) DE602004019524D1 (da)
DK (2) DK2058329T3 (da)
ES (2) ES2353457T3 (da)
HK (1) HK1082752A1 (da)
IL (1) IL172270A (da)
NZ (1) NZ544263A (da)
RU (1) RU2005138368A (da)
WO (1) WO2004108760A2 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
NZ543365A (en) 2003-04-18 2009-02-28 Biogen Idec Inc Polymer-conjugated glycosylated neublastin
ATE490307T1 (de) 2003-05-21 2010-12-15 Genzyme Corp Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind
EP1636260B1 (en) 2003-06-10 2009-02-18 Nsgene A/S Improved secretion of neublastin
US7598059B2 (en) * 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
CN1897977A (zh) * 2003-10-20 2007-01-17 Ns基因公司 帕金森氏病的体内基因治疗
US8722862B2 (en) * 2004-08-19 2014-05-13 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
EA013565B1 (ru) * 2004-08-19 2010-06-30 Байоджен Айдек Ма Инк. Варианты полипептидов нейбластина, способы их получения и их применение
ES2864039T3 (es) 2005-05-20 2021-10-13 Lonza Biologics Plc Expresión de alto nivel de un anticuerpo recombinante en una célula huésped de mamífero
EP1937295A2 (en) * 2005-10-11 2008-07-02 NS Gene A/S Treatment of retinopathies using gfr 3 agonists
WO2007078922A2 (en) * 2005-12-30 2007-07-12 Neurotech Usa Inc. Micronized device for the delivery of biologically active molecules and methods of use thereof
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
EP1993590B1 (en) * 2006-03-01 2013-12-25 Biogen Idec MA Inc. Compostions and methods for administering gdnf ligand family proteins
TWI445544B (zh) 2007-05-01 2014-07-21 Biogen Idec Inc 增進血管形成之組合物及方法
EP2048237A1 (en) 2007-10-05 2009-04-15 Avir Green Hills Biotechnology Research Development Trade Ag Replication deficient Influenza virus for the expression of heterologous sequences
US9080183B2 (en) * 2007-06-29 2015-07-14 Hoffmann-La Roche Inc. Promoter
US20110135648A1 (en) * 2007-08-08 2011-06-09 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
KR20170073614A (ko) * 2008-03-21 2017-06-28 티슈진, 인코포레이티드 추간디스크 퇴행 치료용 조성물
EP2281047B1 (en) * 2008-04-15 2020-04-08 Genzyme Corporation Methods to produce rod-derived cone viability factor (rdcvf)
JP5897335B2 (ja) 2009-01-23 2016-03-30 エヌエスジーン・アクティーゼルスカブＮｓＧｅｎｅ Ａ／Ｓ 改良された細胞株及びカプセル化細胞生体送達におけるその使用
US20120021039A1 (en) * 2009-01-23 2012-01-26 Nsgene A/S Expression of neuropeptides in mammalian cells
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
ES2947311T3 (es) * 2015-05-07 2023-08-04 Univ South Florida Gen UBE3A modificado para un enfoque de terapia génica para el síndrome de Angelman
GB201519086D0 (en) * 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
JP2019513224A (ja) * 2016-03-04 2019-05-23 エヌジーエム バイオファーマシューティカルス，インコー 体重を調節するための組成物及び方法
CN108610398B (zh) * 2018-01-15 2020-08-11 武汉海特生物制药股份有限公司 一段功能序列及在分泌蛋白表达中的应用
US20200385710A1 (en) 2018-02-08 2020-12-10 Applied Stemcell, Inc. Methods for screening variant of target gene
JP2022516053A (ja) * 2018-12-21 2022-02-24 グロリアーナ・セラピューティクス・ソシエテ・ア・レスポンサビリテ・リミテ 哺乳動物細胞培養物によって生産されるニューブラスチン抗体

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
EP0228458B2 (en) 1985-07-05 1997-10-22 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
DE3852823T2 (de) 1987-09-11 1995-05-24 Hughes Howard Med Inst Transduktionsveränderte fibroblasten und ihre anwendung.
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5487739A (en) 1987-11-17 1996-01-30 Brown University Research Foundation Implantable therapy systems and methods
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5156844A (en) 1987-11-17 1992-10-20 Brown University Research Foundation Neurological therapy system
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
JP2791418B2 (ja) * 1987-12-02 1998-08-27 株式会社ミドリ十字 異種蛋白質の製造方法、組換えｄｎａ、形質転換体
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
IL95330A0 (en) * 1989-08-11 1991-06-30 Lilly Co Eli Expression of a functional insect specific toxin gene in mammalian cells
WO1992019195A1 (en) 1991-04-25 1992-11-12 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
GEP20002243B (en) 1991-09-20 2000-09-25 Amgen Inc Glial Derived Neurotrophic Factor
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
EP0708670A4 (en) 1993-06-23 1998-07-01 Cytotherapeutics Inc METHOD AND APPARATUS FOR HERMETICALLY CLOSING IMPLANTABLE MEMBRANE ENCAPSULATING DEVICES
WO1995005452A2 (en) 1993-08-12 1995-02-23 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5656465A (en) 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
US5677158A (en) 1995-06-07 1997-10-14 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US5904144A (en) 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6027721A (en) 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
US6054142A (en) 1996-08-01 2000-04-25 Cyto Therapeutics, Inc. Biocompatible devices with foam scaffolds
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
JP2002502822A (ja) * 1998-02-10 2002-01-29 オレゴン ヘルス サイエンシーズ ユニバーシティー 骨芽細胞の前駆細胞による骨欠損の治療
US6303136B1 (en) 1998-04-13 2001-10-16 Neurotech S.A. Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane
US6683058B1 (en) 1998-04-15 2004-01-27 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
ES2324540T3 (es) 1998-05-27 2009-08-10 Genzyme Corporation Vectores aav para la fabricacion de medicamentos para la administracion potenciada por conveccion.
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US20020055467A1 (en) 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
HU226073B1 (en) 1998-07-14 2008-04-28 Janssen Pharmaceutica Nv Neurotrophic growth factor
US6284540B1 (en) 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
IL126562A0 (en) * 1998-10-14 1999-08-17 Interpharm Lab Ltd Expression and secretion of icil-1 receptor antagonist type ii
US6361741B1 (en) 1999-02-01 2002-03-26 Alcoa Inc. Brazeable 6XXX alloy with B-rated or better machinability
US6420345B1 (en) * 1999-03-01 2002-07-16 Cell Genesys, Inc. Methods and reagents for inhibiting angiogenesis
US6361771B1 (en) * 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
CA2385929A1 (en) 1999-10-29 2001-05-03 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Use of gdnf for treating corneal defects
US6866851B1 (en) * 1999-12-28 2005-03-15 Washington University GFRα1-RET specific agonists and methods therefor
JP2003534787A (ja) 2000-05-26 2003-11-25 カイロン コーポレイション レンチウイルスベクターを使用する神経細胞の形質導入の方法
GB0018876D0 (en) * 2000-08-01 2000-09-20 Applied Research Systems Method of producing polypeptides
CN1547483A (zh) * 2000-12-22 2004-11-17 �����ɷ� Artemin-gdnf配体家族的一个成员的新用途
JP4259868B2 (ja) * 2001-02-01 2009-04-30 バイオジェン・アイデック・エムエイ・インコーポレイテッド ニューブラスチンのポリマー結合体および同様の使用方法。
NZ529126A (en) * 2001-03-28 2010-07-30 Biogen Idec Inc Use of neublastin polypeptides for treating allodynia, hyperalgesic pain and phantom pain
NZ543365A (en) * 2003-04-18 2009-02-28 Biogen Idec Inc Polymer-conjugated glycosylated neublastin
EP1636260B1 (en) 2003-06-10 2009-02-18 Nsgene A/S Improved secretion of neublastin
US7598059B2 (en) * 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
NZ547185A (en) 2003-10-20 2009-03-31 Nsgene As In vivo gene therapy of parkinson's disease

Also Published As

Publication number Publication date
DE602004019524D1 (de) 2009-04-02
CN100475846C (zh) 2009-04-08
IL172270A (en) 2015-04-30
RU2005138368A (ru) 2006-07-27
NZ544263A (en) 2009-04-30
WO2004108760A3 (en) 2005-04-07
EP2058329B1 (en) 2010-08-18
AU2004245175C1 (en) 2010-03-18
HK1082752A1 (en) 2006-06-16
EP1636260A2 (en) 2006-03-22
KR20060031618A (ko) 2006-04-12
US7601518B2 (en) 2009-10-13
US20050089960A1 (en) 2005-04-28
DE602004028769D1 (de) 2010-09-30
ATE423134T1 (de) 2009-03-15
AU2004245175B2 (en) 2009-10-15
JP5623685B2 (ja) 2014-11-12
ATE478092T1 (de) 2010-09-15
ES2323066T3 (es) 2009-07-06
CA2527914A1 (en) 2004-12-16
CA2527914C (en) 2014-10-28
JP2007535898A (ja) 2007-12-13
AU2004245175A1 (en) 2004-12-16
DK2058329T3 (da) 2010-12-06
WO2004108760A2 (en) 2004-12-16
CN1835971A (zh) 2006-09-20
ES2353457T3 (es) 2011-03-02
BRPI0411243A (pt) 2006-07-11
EP2058329A1 (en) 2009-05-13
EP1636260B1 (en) 2009-02-18
IL172270A0 (en) 2006-04-10

Similar Documents

Publication Publication Date Title
DK1636260T3 (da) Forbedret udskillelse af Neublastin
ATE533839T1 (de) Phytasenvarianten
ATE489458T1 (de) Detoxifizym mit aktivität zur transformation von aflatoxin sowie das dafür codierende gen
DK1622921T3 (da) Varianter af beta-glucosidaser
EA200600746A1 (ru) Конструкции нуклеиновых кислот
DE60042969D1 (de) Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren
DE69833784D1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
ATE536409T1 (de) Unkrautbekämpfungsstoffwechselproteine, gene dafür und ihre verwendung
DE602005009738D1 (de) Verfahren zur herstellung und sekretion modifizierter peptide
ATE469217T1 (de) Den phosphorsäure-metabolismus, den kalzium- metabolismus, verkalkung und den vitamin d- metabolismus kontrollierende polypeptide sowie für diese kodierende dna-moleküle
ATE476507T1 (de) Transkriptionsfaktor aus arabidopis thaliana sowie codierendes gen und verwendung davon
SI2332972T1 (en) New beta-actin and rpS21 promoters and their use
ES2185146T3 (es) Receptores de netrina.
RU2009130108A (ru) Секретируемая люцифераза mluc7 и ее применение
WO2005067410A3 (en) Synthetic nucleic acids from aquatic species
ATE445009T1 (de) Signalpeptid zur herstellung eines polypeptids
HUP0003564A2 (hu) Protein kinázok és alkalmazásuk
AR025482A1 (es) Secuencia de adn que codifica una proteina capaz de ligarse a traf; vector que comprende dicha secuencia; celulas huespedes transformadas con dicho vector;proteinas iren codificadas por dicha secuencia; metodo para producir dicha proteina; anticuerpos especificos para dichas proteinas; metodo para m
DE60026569D1 (de) Zusammensetzungen auf der basis von gfr-alpha-4 und deren anwendungen
EA200200286A1 (ru) Ген prv-1 и его применение
ATE317896T1 (de) Polypeptide mit glucanotransferase aktivität und dafür kodierende nukleinsäuren
DE602004019556D1 (de) Neues plexin-polypeptid, dieses codierende dna und verwendung davon
DE602005024974D1 (de) Polypeptid mit einer Delta-5-Fettsäure-Desaturierungsaktivität, für das Polypeptid codierendes Polynukleotid und Verwendung davon.
ATE376768T1 (de) Transgenes tiermodell für alzheimer-erkrankung
WO2004057940A3 (en) Canine dioxin/aryl hydrocarbon receptor sequences